In vivo effects of new inhibitors of catechol-O-methyl transferase

British Journal of Pharmacology

Volumn 126, Issue 7, 1999, Pages 1667-1673

  Rivas, Emilia ^a   De Ceballos, Maria L ^b   Nieto, Ofelia ^c   Fontenla, José Angel ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b INSTITUTO CAJAL   (Spain)

^c INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

Author keywords

Amines; Antiparkinsonian therapy; COMT; L DOPA; Parkinson's disease

Indexed keywords

2' FLUORO 3,4 DIHYDROXY 5 NITROBENZOPHENONE; 3(3 HYDROXY 4 METHOXY 5 NITROBENZYLIDENE) 2,4 PENTANEDIONE; AMINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; LEVODOPA; NITECAPONE; QO IA; QO IIR; RESERPINE; UNCLASSIFIED DRUG; [2 (3,4 DIHYDROXY 2 NITROPHENYL)VINYL]PHENYL KETONE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; HYPOTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032933421     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702474     Document Type: Article

References (28)

1. ADLER, C.H., SINGER, C., O'BRIEN, C., HAUSER, R.A., LEW, M.F., MAREK, K.L., DORFLINGER, E., PEDDER, S., DEPTULA, D. & YOO, K. (1998). Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch. Neurol., 55, 1089-1095.
2. BÄCKSTRÖM, R., HONKANEN, E., PIPPURI, A., KAIRISALO, P., PYSTYNEN, J., HEINOLA, K., NISSINEN, E., LINDÉN, I.-B., MÂNNISTO, P.T. & PHTO, P. (1989). Synthesis of some novel potent and selective catechol-O-methyltransferase inhibitors. J. Med. Chem., 32, 841-846.
3. BARTHOLINI, G. & PLETSCHER, A. (1975). Decarboxylase inhibitors. Pharmacol. Ther., 1, 407-421.
4. BAAS, H., BEISKE, A.G., GHIKA, J., JACKSON, M., OERTEL, W.H., POEWE, W. & RANSMAYR, G. (1998). Catechol-O-methyltransferase inhibition with tolcapone reduces the 'wearing off' phenomenon and levodopa requirements in fluctuating parkinsonian patients. Neurology, 50(Suppl. 5), S46-S53.
5. BORGULYA, J., BRUDERER, H., BERNAUER, K., ZÜRCHER, G. & DA PRADA, G. (1989). Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives: synthesis and structure-activity studies. Helv. Chim. Acta, 72, 952-968.
6. CEDARBAUM, J.M., LEGER, G. & GUTTMAN, M. (1991). Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: Implications for the treatment of Parkinson's disease. Clin. Pharmacol., 14, 330-342.
7. GULDBERG, H.C. & MARSDEN, C.A. (1975). Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol. Rev., 27, 135-206.
8. JORGA, K.M., SEDEK, G., FOTTELER, B., ZÜRCHER, G., NIELSEN, T. & AITKEN, J.W. (1997). Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin. Pharmacol. Ther., 62, 300-310.
9. KOPIN, I. (1985). Catecholamine metabolism: basic aspects and clinical significance. Pharmacol. Rev., 31, 333-363.
10. LINDÉN, I.-B., NISSINEN, E., ETEMADZADEH, E., KAAKKOLA, S., MÄNNISTÖ, P. & POHTO, P. (1988). Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease. J. Pharmacol. Exp. Ther., 247, 289-293.
11. MAJ, J, ROGÓZ, Z., SKUZA, G., SOWINSKA, H. & SUPERATA, J. (1990). Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with potential therapeutic activity in Parkinson's disease. J. Neural. Trans. [P-D Sect], 2, 101-112.
12. MÄNNISTÖ, P.T. & KAAKKOLA, S. (1990). Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol. Toxicol., 66, 317-323.
13. MÄNNISTÖ, P.T., KAAKKOLA, S., NISSINEN, E., LINDÉN, I.-B. & POHTO, P. (1988). Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci., 43, 1465-1471.
14. MÄNNISTÖ, P.T. & TUOMAINEN, P. (1991). Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat. Naunyn-Schmiedeberg's Arch. Pharmacol., 344, 412-418.
15. MÄNNISTÖ, P.T., TUOMAINEN, P. & TUOMINEN, R.K. (1992). Different in vivo properties of three new inhibitors of catechol-O-methyltransferase in the rat. Brit. J. Pharmacol., 105, 569-574.
16. MUENTER, M.D., DINAPOLI, R.P., SHARPLESS, N.S. & TYCE, G.M. (1973). 3-O-methyldopa, L-DOPA and trihexyphenidyl in the treatment of Parkinson's disease. Mayo Clin. Proc., 48, 173-178.
17. NISSINEN, E., LINDÉN, I.-B., SCHULTZ, E., KAAKKOLA, S., MÄNNISTÖ, P.T. & POHTO, P. (1988). Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur. J. Pharmacol., 153, 263-269.
18. NISSINEN, E., LINDÉN, I.-B., SCHULTZ, E. & POHTO, P. (1992). Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor Entacapone. Naunyn-Schmiedeberg's Arch. Pharmacol., 346, 262-266.
19. PAPAVASILOUS, P.S., COTZIAS, G.C. & DUBY, S.E. (1972). Levodopa in parkinsonism: Potentiation of central effects with a peripheral inhibitor. N. Engl. J. Med., 285, 8-14.
20. PÉREZ, R.A., FERNÁNDEZ-ALVÁREZ, E., NIETO, O. & PIEDRAFITA, F.J. (1993). Inhibition of catechol-O-methyltransferase by 1-vinyl derivatives of nitrocatechols and nitroguaiacols. Kinetics of the irreversible inhibition by 3-(3-hydroxy-4-methoxy-5-nitrobenzylidene)-2,4-pentanedione. Biochem. Pharmacol., 45, 1973-1981.
21. PÉREZ, R.A., FERNÁNDEZ-AEVÁREZ, E., NTETO, O. & PIEDRAFITA, F.J. (1994). Kinetics of the reversible tight-binding inhibition of pig liver catechol-O-methyltransferase by [2-(3,4-dihydroxy-2-nitrophenyl)vinyl]phenyl ketone. J. Enzyme Inhib., 8, 123-131.
22. RAJPUT, A.M., MARTIN, W., SAINT-HILAIRE, M.H., DORFLINGER, E. & PEDDER, S. (1997). Tolcapone improves motor function in parkinsonian patients with the 'wearing-off' phenomenon: a double-blind, placebo-conlrolled, multicenter trial. Neurology, 49, 1066-1071.
23. RECHES, A., MIELKE, C.R. & FAHN, S. (1982). 3-O-methyldopa inhibits rotation induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology, 32, 887-888.
24. SANDLER, M., JOHNSON, R., RUTHVEN, D, RIED, J. & CALNE, D. (1974). Transamination is a major pathway of L-DOPA metabolosm following peripheral decarboxylase inhibition. Nature, 247, 364-366.
25. SHARPLESS, N.S., MUENTER, M.D., TYCE, G.M. & OWEN, C.A. (1972). 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during L-dopa therapy of patients with Parkinson's disease. Clin. Chim. Acta, 37, 359-369.
26. TÖRNWALL, M., TUOMAINEN, P. & MÄNNISTÖ, P.T. (1993). Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase. Eur. J. Pharmacol., 239, 239-245.
27. YAMAMOTO, M., YOKOCHI, M., KUNO, S., HATTORI, Y., TSUKAMOTO, Y., NARABAYASHI, H., TOHGI, H., MIZUNO, Y., KOWA, H., YANAGISAWA, N. & KANAZAWA, I. (1997). Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. J. Neural. Trans., 104, 229-236.
28. ZÜRCHER, G., COLZI, A. & DA PRADA, M. (1990). Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J. Neural. Transm., 32, 375-380.